LIVE Bonus Presentations
Tuesday, October 13, 2020 |
||
7:00 pm - 7:45 pm (Eastern) |
Studies in Clearance: SKYRIZI for moderate to severe plaque psoriasis (Non-CME)
|
Wednesday, October 14, 2020 |
||
12:00 pm - 12:45 pm (Eastern) |
What Sets Taltz Apart: An Overview of Long-Term Safety and Efficacy—Featuring Data in New Patient Population (Non-CME)
|
Wednesday, October 14, 2020 |
||
7:00 pm - 7:45 pm (Eastern) |
FDA-Approved Label Expansion Progress Your Topical Patients to the Next Step: An Oral Treatment With Data for Moderate to Severe Scalp Psoriasis (Non-CME)
|
Thursday, October 15, 2020 |
||
4:45 pm -5:45 pm (Eastern) |
Revolutionizing AD for Children (6-11 Years of Age) With Uncontrolled Moderate-to-Severe Atopic Dermatitis (Non-CME)
|
Friday, October 16, 2020 |
||
10:30 am – 11:15 am (Eastern)
|
Tremfya (guselkumab)
|
Jointly Provided By

